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Long interspersed elements 1 (LINE-1) occupy at
least 17% of the human genome and are its only
active autonomous retrotransposons. However, the
host factors that regulate LINE-1 retrotransposition
are not fully understood. Here, we demonstrate that
the Aicardi-Goutie`res syndrome gene product
SAMHD1, recently revealed to be an inhibitor of
HIV/simian immunodeficiency virus (SIV) infectivity
and neutralized by the viral Vpx protein, is also a
potent regulator of LINE-1 and LINE-1-mediated
Alu/SVA retrotransposition. We also found that
mutant SAMHD1s of Aicardi-Goutie`res syndrome
patients are defective in LINE-1 inhibition. Several
domains of SAMHD1 are critical for LINE-1 regula-
tion. SAMHD1 inhibits LINE-1 retrotransposition in
dividing cells. An enzymatic active site mutant
SAMHD1maintained substantial anti-LINE-1 activity.
SAMHD1 inhibits ORF2p-mediated LINE-1 reverse
transcription in isolated LINE-1 ribonucleoproteins
by reducing ORF2p level. Thus, SAMHD1 may be a
cellular regulator of LINE-1 activity that is conserved
in mammals.
INTRODUCTION
LINE-1 is the only active autonomous retroelement in humans
and can produce new genomic insertions mediated by its
encoded endonuclease (Feng et al., 1996) and reverse transcrip-
tase (Mathias et al., 1991) activities. LINE-1s make up at least
17% of the human genome (Beck et al., 2011; Brouha et al.,
2003; Hancks and Kazazian, 2012; Lander et al., 2001). Other
nonautonomous retroelements, such as Alu and SVA, complete
their retrotransposition process by a mechanism mediated by1108 Cell Reports 4, 1108–1115, September 26, 2013 ª2013 The AuLINE-1 proteins and account for approximately 1 million and
3,000 copies, respectively (Lander et al., 2001; Ostertag et al.,
2003; Wang et al., 2005). Recent data have suggested that the
activity of retroelements such as LINE-1, Alu, and SVA can
lead to various diseases (Beck et al., 2011; Hancks and Kaza-
zian, 2012).
SAMHD1 mutations can cause Aicardi-Goutie`res syndrome
(AGS), which is characterized as an improper immune activation
resulting from the accumulation of intracellular DNA (Rice et al.,
2009; Thiele et al., 2010; Xin et al., 2011). SAMHD1 is also a
potent cellular restriction factor against retroviruses such as
HIV and simian immunodeficiency virus (SIV) (Hrecka et al.,
2011; Laguette et al., 2011), with a deoxynucleoside triphos-
phate triphosphohydrolase (dNTPase) activity linked to retroviral
restriction (Goldstone et al., 2011; Kim et al., 2012; Lahouassa
et al., 2012; Powell et al., 2011). SAMHD1 inhibits retroviruses
in nondividingmyeloid cells and resting CD4+ T cells by depleting
dNTP levels (Baldauf et al., 2012; Descours et al., 2012),
although recent studies suggested that the phosphorylation
status of SAMHD1 (T592) is also important for the anti-HIV activ-
ity (Cribier et al., 2013; White et al., 2013b). However, the ability
of SAMHD1 to inhibit endogenous retroelements such as LINE-1
has not been previously reported.
RESULTS
The SAMHD1 Protein Is a Potent Cellular Factor
Suppressing LINE-1 Activity
To determine whether LINE-1 is a potential target of SAMHD1,
we evaluated the effect of SAMHD1 on LINE-1 retrotransposition
using a well-established reporter system in HEK293T cells
(Moran et al., 1996; Niewiadomska et al., 2007; Ostertag et al.,
2000) (Figure S1A). The LINE-1 construct 99 PUR RPS EGFP
contains an EGFP reporter cassette, interrupted by an intron in
the opposite transcriptional orientation and inserted into the 30
UTR of a retrotransposition-competent L1, L1-RP (Kimberland






Figure 1. Modulation of LINE-1 Retrotransposition by SAMHD1
(A) SAMHD1 suppressed LINE-1 activity in a dose-dependent manner. 99 PUR RPS EGFP (LINE-1) has been previously described (Moran et al., 1996). The
negative control, the defective LINE-1 retrotransposition construct 99 PUR JM111 EGFP (JM111), gave few GFP-positive cells (Figure S1B) and was used as
negative control for flow cytometry gating. VR1012 was the empty vector used as negative control for SAMHD1 expression. SAMHD1-expressing plasmids (100,
250, and 500 ng) were cotransfectedwith LINE-1 into HEK293T cells to examine the possible potency against LINE-1 retrotransposition. EGFP-positive cells were
determined by flow cytometry 4 days after transfection.
(B) SAMHD1 does not affect CMV promoter-driven expression of EGFP.
(C) Depletion of endogenous SAMHD1 with specific siRNA treatment in HEK293T cells enhances LINE-1 activity. The number above the immunoblotting result
indicates the relative amount of SAMHD1 mRNA level (the control siRNA-treated sample was set to 1), which was determined by SAMHD1-specific real-time
PCR. GAPDH mRNA was also monitored as a cellular mRNA control (data not shown).
(D) Transfected SAMHD1 in HEK293T cells inhibits LINE-1 activity but not wild-type SIV or SIVDVpx infection. HEK293T cells were transfected with the empty
vector or SAMHD1 expression vector prior to infection with equal amounts of VSV-G pseudotype SIV WT or SIVDVpx viruses containing EGFP cassette in viral
genome. The transfection efficiency was approximately 90% using similar conditions in a parallel experiment.
(E) Transfected SAMHD1-HA in HEK293T cells was depleted during SIV WT but not SIVDVpx infection.
(F) The active site mutant SAMHD1 D311A maintained substantial activity against LINE-1.
(G) SAMHD1T592A and SAMHD1T592D maintained LINE-1 inhibition activity. All the data in this figure are representative of at least three independent
experiments. The error bars indicated the SD of three replicates within one experiment.
See also Figures S1 and S2.LINE-1 transcript is spliced and reverse transcribed, its comple-
mentary DNA (cDNA) is inserted into the host genome, and the
EGFP reporter gene is expressed from its own CMV promoter.
Construct 99 PUR JM111 EGFP (JM111), which contains two
missense mutations in ORF1 (Moran et al., 1996), produces no
EGFP signal (i.e., it is retrotransposition defective) and was
used as a negative control for retrotransposition (Figure S1C).
99 PUR RPS EGFP generated approximately 0.8%GFP-positive
cells, whereas JM111 produced no EGFP-positive cells (Fig-
ure 1A). The empty vector (VR1012) had no apparent effect on
LINE-1 activity when compared to a no-vector control (Fig-
ure S1D). SAMHD1 potently inhibited LINE-1 retrotranspositionCell Rein a dose-dependent fashion in HEK293T cells (Figure 1A). The
expression of mCherry had no effect on LINE-1 retrotransposi-
tion, whereas fusion protein mCherry-SAMHD1 was still potent
in LINE-1 inhibition (Figures S1E and S1F). SAMHD1 expression
had no apparent effect on cellular proliferation or cellular b-actin
mRNA splicing (Figures S1G and S1H). The LINE-1 assay relies
on CMV promoter-driven EGFP expression as a readout. Under
a similar percentage of EGFP-positive cells, coexpression of
SAMHD1 in a dosemanner with a CMV-EGFP-expressing vector
did not alter the expression of EGFP (Figure 1B), showing
that SAMHD1 does not affect either CMV promoter-mediated
transcription or translation/stability of the EGFP protein.ports 4, 1108–1115, September 26, 2013 ª2013 The Authors 1109
A synthetic human LINE-1 construct (ORFeus-HS) (An et al.,
2011) containing codon-modified ORF1 and ORF2 sequences
and a deleted 50 UTR was also suppressed by SAMHD1 (Figures
S2A and S2B). Because ORFeus-HS contains little authentic
LINE-1 RNA sequence, it appears that SAMHD1 may not target
the cis-sequence of LINE-1. Furthermore, retrotransposition of
Neo-based L1-RP (Kimberland et al., 1999) in HeLa cells was
efficiently inhibited by SAMHD1 (Figures S2A, S2C, and S2D).
Thus, we have demonstrated that SAMHD1 inhibits retrotrans-
position in diverse mammalian LINE-1 systems.
Endogenous SAMHD1 can also function as a LINE-1 inhibitor.
Addition of specific small interfering RNAs (siRNAs) targeting
SAMHD1 resulted in a 230% increase in LINE-1 retrotransposi-
tion in HEK293T cells (Figure 1C). Similar L1 inhibition was
observed when the expression of endogenous SAMHD1 was
reduced by using a SIV Vpx (viral protein X) expression vector,
but not by a mutant VpxQ76A expression vector (defective in
mediating SAMHD1 degradation; Wei et al., 2012) in HEK293T
cells (Figures S2E and S2F).
Although we achieved approximately 90% transfection effi-
ciency as indicated by the efficient degradation of endogenous
SAMHD1 by the transfected Vpx expression vector (Figure S2E)
and the detection of mCherry expression after transfection in
parallel experiments (data not shown), SAMHD1 expression in
HEK293T cells had no obvious effect on the infection of wild-
type SIVsmm (SIV-WT) or SIVsmmDVpx (Figure 1D). It is unlikely
that SIV-WT or SIVsmmDVpx preferentially infected untrans-
fected HEK293T cells, because SIV-WT infection still resulted
in transfected SAMHD1 degradation in these cells (Figure 1E).
SAMHD1 expression also did not inhibit HIV-1 infection in
HEK293T cells (Figure S2G). SAMHD1 restricts the retroviral
reverse transcription in nondividing myeloid cells by depleting
the intracellular dNTP pool (Berger et al., 2011; Goldstone
et al., 2011; Hrecka et al., 2011; Laguette et al., 2011; Lahouassa
et al., 2012; Powell et al., 2011). This dNTP depletion activity is
countered by the active production of dNTPs in the dividing cells
(Manel and Littman, 2011). Our data showing that SAMHD1
cannot suppress HIV/SIV infection in HEK293T cells are consis-
tent with this model. We also observed that SAMHD1 did not
inhibit HBV replication (which also requires dNTPs during
reverse transcription) in HEK293T cells (Figure S2H). Therefore,
SAMHD1may inhibit LINE-1 and retroviruses through apparently
distinct mechanisms. Consistent with this idea, the SAMHD1
mutant D311A, which is defective for dNTPase activity (Gold-
stone et al., 2011), maintained the ability to inhibit LINE-1 retro-
transposition (Figure 1F). Active site mutants of SAMHD1 have
been reported to lack anti-HIV-1 or SIVDVpx activity (Laguette
et al., 2011; Lahouassa et al., 2012). These results suggest that
dNTPase activity may not be critical for SAMHD1-mediated
LINE-1 inhibition. We have also observed that phosphorylation
status of SAMHD1 (T592), which is important for HIV-1 restriction
(Cribier et al., 2013; White et al., 2013b), did not affect LINE-1
inhibition (Figure 1G).
AGS-Related Mutations Compromise the Ability
of SAMHD1 to Suppress LINE-1 Activity
Specific SAMHD1 point mutations, internal deletions, and
carboxyl-terminal truncations (Figure 2A) can cause AGS (Dale1110 Cell Reports 4, 1108–1115, September 26, 2013 ª2013 The Auet al., 2010; Rice et al., 2009; Thiele et al., 2010; Xin et al.,
2011). An examination of several SAMHD1 mutants that have
been identified in AGS patients indicated that they all show
significantly reduced LINE-1 inhibition (p < 0.01 versus wild-
type SAMHD1), even when expressed at levels comparable to
wild-type SAMHD1 (Figures 2B and 2C). LINE-1 reverse tran-
scription occurs on genomic DNA in the nucleus through a pro-
cess called target-primed reverse transcription (Luan et al.,
1993). SAMHD1 has also been localized to the nucleus (Rice
et al., 2009). Thus, nuclear localization could be required for
SAMHD1-mediated LINE-1 inhibition. However, we found that
the SAMHD1 point mutants and SAMHD1 truncation mutants
maintained a nuclear localization in live HEK293T cells (Fig-
ure S3A; data not shown).
We further examined regions in SAMHD1 that are important for
its anti-LINE-1 activity (Figure 2A). We observed that SAMHD1
mutants lacking the partial HD domain (SAMHD1 D162-335)
and amino acids 113–136 (SAMHD1 D113-136) had weaker
activity against LINE-1 than did full-length SAMHD1 (Figures
S3B and S3C). On the other hand, deletion of the SAM domain
(SAMHD1 D42-109 had an increased effect on LINE-1 inhibition
(Figures S3B and S3C). However, deletion of the N-terminal
region including the linker region abolished SAMHD1-mediated
LINE-1 inhibition (Figure 2D). It is worth noting that deletion of
SAMHD1 SAM domain reduced its dNTPase and anti-HIV-1
activities (White et al., 2013a). However, SAM domain deletion
SAMHD1 mutant still inhibited LINE-1 (Figures S3B and S3C),
consistent with the argument that SAMHD1 inhibits LINE-1 and
HIV-1/SIV through distinct mechanisms. Thus, in SAMHD1, the
linker region between the SAM and HD domains, and possibly
the HD domain itself, is critical for LINE1 inhibition. Interestingly,
the AGS-related SAMHD1 point mutants that have a reduced
capacity for LINE-1 inhibition are all clustered in these regions.
LINE-1 Suppression Is a Conserved Feature among
Mammalian SAMHD1 Proteins
We were also interested in the LINE-1 inhibition potency of
SAMHD1 from other animals. SAMHD1 from the nonhuman pri-
mates Nomascus leucogenys (NL) and Macaca mulatta (MM)
showed strong LINE-1 inhibition when compared to human
SAMHD1 (Figure 3A). SAMHD1 from the primate Pongo abelii
(PA) had a slightly weaker anti-LINE-1 activity than that of human
SAMHD1 (Figure 3A). Also, SAMHD1 from both Canis lupus
familiaris (CLF) and Bos taurus (BT) had strong anti-LINE-1 activ-
ity (Figure 3B). Interestingly, human and Mus musculus (Mus)
SAMHD1 could potently suppress the retrotransposition of
LINE-1 from both human and mouse (Figures 3C and 3D).
Thus, LINE-1 inhibition appears to be a conserved feature of
mammalian SAMHD1 proteins, and SAMHD1 protein functions
through a general mechanism to suppress LINE-1 from different
species.
Inhibition of ORF2p-Mediated LINE-1 Reverse
Transcription by SAMHD1
Several attempts were made to identify the potential target of
SAMHD1 in LINE-1 retrotransposition. We first tested the effect
of SAMHD1 on LINE-1 gene expression. A few transcription fac-
tors that interact with LINE-1s have been identified (Becker et al.,thors
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Figure 2. AGS-Related SAMHD1 Mutants Have Reduced Potency against LINE-1 Retrotransposition
(A) A diagram indicating SAMHD1 mutant constructs used in this figure. Positions of AGS-related single amino acid mutations are indicated above the wild-type
SAMHD1 cartoon.
(B) SAMHD1 mutant proteins with single amino acid substitutions detected from AGS patients have compromised activity against LINE-1.
(C) Naturally occurring SAMHD1 deletion mutants detected in AGS patients also show reduced LINE-1 inhibition.
(D) Both SAMHD1 D2-161 and D2-335 completely lost their LINE-1 inhibition activity. All the data in this figure are representative of at least three independent
experiments. The error bars indicated the SD of three replicates within one experiment.
See also Figure S3.1993; Dai et al., 2012; Harris et al., 2009; Tche´nio et al., 2000;
Yang et al., 2003). HnRNPL (Peddigari et al., 2013) and RNA heli-
case MOV10 (Goodier et al., 2012) have been reported to influ-
ence LINE-1 ORF1 expression. We have confirmed in our assay
system that HnRNPL and MOV10 could reduce LINE-1 ORF1p
expression (Figure 4A). Unlike HnRNPL and MOV10, SAMHD1
did not alter LINE-1 ORF1p expression (Figure 4A). LINE-1 repli-
cation requires reverse transcription of its own RNA genome
using ORF2p. An in vitro LEAP reverse transcriptase assay has
been developed (Kulpa and Moran, 2006) to assess the function
of ORF2p in LINE-1 ribonucleoprotein (RNP) complexes (Fig-
ure 4B). LINE-1 RNPs from an ORF1-tagged LINE-1 construct
(Goodier et al., 2012) were isolated from transfected HEK293T
cells in the absence or presence of SAMHD1. SAMHD1 did not
affect the isolation of LINE-1 RNPs, as indicated by the detection
of ORF1 protein or LINE-1 RNA (Figure 4C). However, ORF2p-
mediated endogenous reverse transcription of LINE-1 RNA
(LEAP products) was significantly suppressed in the presence
of SAMHD1 (Figure 4C, lane 2) when compared to its absence
(lane 1). Quantitative real-time PCR indicated that SAMHD1Cell Recaused an 83% reduction of the ORF2-mediated endogenous
reverse transcription of LINE-1 RNA (Figure 4D). Further investi-
gation indicated that SAMHD1 reduced the expression of
ORF2p, by 62% in average (Figures 4E and S4A). Moreover,
SAMHD1 inhibited ORF2p-mediated Alu and SINE-VNTR-Alu
(SVA) retrotransposition activity (Figures S4B–S4E).
DISCUSSION
This study has identified LINE-1, Alu, and SVA retroelements as
the potential targets of SAMHD1. We have determined that hu-
man SAMHD1 inhibits LINE-1 activity using various established
human and mouse LINE-1 retrotransposition assay systems
(Moran et al., 1996; Kimberland et al., 1999; Ostertag et al.,
2000; Han and Boeke, 2004; An et al., 2011). SAMHD1 can
also inhibit the retrotransposition of a modified human synthetic
LINE-1 (An et al., 2011) that contains little authentic LINE-1
sequence. Thus, SAMHD1 may not target the LINE-1 cis-RNA
sequence. Consistent with this argument, we observed no
detectable interaction of SAMHD1 with endogenous LINE-1ports 4, 1108–1115, September 26, 2013 ª2013 The Authors 1111
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Figure 3. Diverse Mammalian SAMHD1
Proteins Inhibit LINE-1 Retrotransposition
(A) Primate SAMHD1 proteins are potent inhibitors
of human LINE-1 activity. HS, Homo sapiens; NL,
Nomascus leucogenys; PA, Pongo abelii; MM,
Macaca mulatta.
(B) SAMHD1 from mammals shows strong inhibi-
tion of human LINE-1, whereas that from chicken
does not. CLF, Canis lupus familiaris; BT, Bos
Taurus.
(C and D) Comparing to human SAMHD1, greater
suppression of either human LINE-1 (Figure 3C)
or codon optimized murine LINE-1 (Figure 3D)
was observed for murine SAMHD1. Mus, Mus
musculus. All the data in this figure are represen-
tative of at least three independent experiments.
The error bars indicated the SD of three replicates
within one experiment.RNA, although LINE-1 RNA binding with ORF1 protein was
readily detected (data not shown).
The effect of SAMHD1 on LINE-1 activity appeared to be
different from other cellular regulators such as HnRNPL and
MOV10. HnRNPL (Peddigari et al., 2013) and MOV10 (Goodier
et al., 2012) have been observed to affect LINE-1 ORF1 expres-
sion. On the other hand, we have observed that SAMHD1 did not
alter LINE-1 ORF1p expression (Figure 4A). However, SAMHD1
reduced ORF2p expression and suppressed ORF2p-mediated
LINE-1 reverse transcription in purified LINE-1 RNP. Further-
more, SAMHD1 also inhibited ORF2p-mediated Alu and SVA ret-
rotransposition. Thus, LINE-1ORF2pmay be a potential target of
SAMHD1.
Interestingly, it seems that SAMHD1 may inhibit retroviruses
and retrotransposons through different mechanisms. SAMHD1
inhibits HIV/SIV in nondividing but not dividing cells. In contrast,
LINE-1 inhibition by SAMHD1 is observed in dividing cells.
SAMHD1’s dNTPase activity depends on residues H167,
H206, D207, and D311 within the HD domain (Aravind and Koo-
nin, 1998; Goldstone et al., 2011; Powell et al., 2011) and is
crucial for retroviral inhibition because mutations at H206/D207
compromise both enzymatic activity and antiviral potency (Kim
et al., 2012; Laguette et al., 2011; Lahouassa et al., 2012). How-1112 Cell Reports 4, 1108–1115, September 26, 2013 ª2013 The Authorsever, in our study, the D311A mutation,
which depletes the hydrolase activity of
SAMHD1 (Goldstone et al., 2011), still
functions as a LINE-1 inhibitor. Eluci-
dating such a mechanism would provide
additional critical information to increase
our understanding of the process of ret-
rotransposition, as well as providing a
potential explanation for SAMHD1 muta-
tions leading to AGS.
Thus far, five genes (TREX1,
RNASEH2A, RNASEH2B, RNASEH2C,
and SAMHD1) have been linked to AGS
and are related to an inability to remove
cellular nucleotide debris intracellularly
(Ali et al., 2006; Crow et al., 2006; Riceet al., 2009; Thiele et al., 2010; Xin et al., 2011). There is no direct
link between LINE-1 activity and the cellular immune response;
however, it has recently been suggested that LINE-1 activity is
linked to both interferon expression and selected autoimmune
disorders (Crow, 2010; Mavragani and Crow, 2010). A recent
report concluded that LINE-1 activity is upregulated in TREX1
knockout cells, suggesting that TREX1 is a LINE-1 inhibitor (Stet-
son et al., 2008). Here, we provide evidence that another AGS-
related protein, SAMHD1, is also a potent LINE-1 suppressor.
AGS-related mutations compromise the potency of SAMHD1
against LINE-1 retrotransposition. AGS-related mutations also
compromised TREX1’s potency against LINE-1 (Stetson et al.,
2008). Interestingly, reverse transcriptase inhibitors could
reduce disease symptoms generated in TREX1-knockout mice
(Beck-Engeser et al., 2011). Further investigation is required to
understand the relationship between retroelements such as
LINE-1, AGS-suspected genes, and AGS itself.EXPERIMENTAL PROCEDURES
Cell Culture and LINE-1 Retrotransposition Assay
HEK293T cells and HeLa-HA cells were grown in DMEM medium with 10%
FBS (HyClone), GlutaMax, and Pen-strep (Invitrogen). All transfections used
A B
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Figure 4. SAMHD1 Inhibits LINE-1 ORF2p-Mediated Endogenous Reverse Transcription in LINE-1 RNP
(A) SAMHD1 did not affect the expression of the LINE-1 ORF1 protein. HEK293T cells were transfected with the pc-L1-1FH vector plus the empty vector VR1012
or the expression vector for SAMHD1, HnRNPL, or MOV10. ImageJ software (NIH) was used to quantitate ORF1 band intensities, and their absolute readings are
indicated above the immunoblot.
(B) A diagram of the LEAP assay. The LINE-1 RNP (from pc-L1-1FH) was produced from transfected HEK293T cells and purified by ultracentrifugation through a
sucrose cushion as previously described. The LEAP primer, containing a linker region (dashed line), was used to precisely target onto LINE-1 mRNA, and the
reverse transcription occurred with the assistance of the ORF2 protein. Synthesized cDNA was then amplified through standard PCR with two primers (dash
arrows) targeting to LINE-1 and the linker.
(C) SAMHD1 reduced the reverse transcription efficiency mediated by ORF2p in LINE-1 RNPs. The amount of ORF1 proteins in isolated LINE-1 RNPs in the
absence or presence of SAMHD1was determined by immunoblotting using an anti-HA antibody. LINE-1 RNAwas examined by using the LEAP primer andMuLV
reverse transcriptase for cDNA synthesis, followed by PCR amplification.
(D) Quantitative real-time PCR analysis of LEAP products and LINE-1 RNA RT-PCR products.
(E) ORF2p level was lowered by 62% in average, with the presence of exogenous SAMDH1 protein. The bar chart was based on five independent experiments.
The error bars indicated the SD.
See also Figure S4.Lipofectamine 2000 (Invitrogen) reagent. HeLa-HA cells were a gift from J.V.
Moran (University of Michigan).
The human L1 plasmids 99 PUR L1RP EGFP (L1) and 99 PUR JM111 EGFP
(JM111, as a negative control) have been previously described (Ostertag et al.,
2000). Similar protocols were also applied to either the synthetic human LINE-
1 sL1-ORFeus-HS (An et al., 2011) or the murine LINE-1 plasmid ORFeus (gifts
of Dr. J.D. Boeke) (Han and Boeke, 2004). In brief, LINE-1 plasmid was trans-
fected into HEK293T cells at 2 mg per well in 12-well plates, together with
VR1012 or one of the test plasmids. The cells were selected by the addition
of puromycin (final concentration, 5 mg/ml) at 48 hr posttransfection. GFP-pos-
itive cells were examined 48 hr later by flow cytometry using FACSCalibur.
Gating exclusions were based on background fluorescence of the plasmid
99 PUR JM111 EGFP, an L1 construct containing two point mutations in
ORF1 that completely abolish retrotransposition; 10,000 single-cell events
per sample were gated and analyzed using CellQuest Pro (v.5.2). For
the mneoI-based LINE-1 retrotransposition assay, 1 mg LcRPS-mneoI was
cotransfected in 6-well plates with 0.5 mg empty vector or the SAMHD1
expression vector into HEK293T cells. At 4 days posttransfection, selection
with G418 was initiated and continued for 13 days. The cells in T75 flasksCell Rewere fixed with PBS/paraformaldehyde/glutaraldehyde, and colonies stained
with 0.4% Giemsa.
LEAP Assays and RT–PCR
The LINE-1 construct containing FLAG-HA-tagged ORF1, pc-L1-1FH, has
been described (Goodier et al., 2012). It was cotransfected in the absence
or presence of the SAMHD1 expression vector into HEK293T cells. At
2 days after transfection, LINE-1 RNPs were isolated by ultracentrifugation
through a sucrose cushion as previously described (Kulpa and Moran,
2006). The LINE-1 RNP sample (2 ml) was added to each cDNA extension
reaction (LEAP) as previously described (Kulpa and Moran, 2006), using
the 30 RACE adaptor NV: 50-GCGAGCACAGAATTAATACGACTCACTATAGG
TTTTTTTTTTTTVN-30 as primer. Also, LINE-1 RNA was extracted from the
LINE-1 RNP, treated with TURBO DNase (Invitrogen), and reverse transcribed
using 30 RACE adaptor NV as primer and MuLV RT with a High Capacity cDNA
Reverse Transcription Kit (ABI Applied Biosystems). PCR was performed as
previously described (Kulpa and Moran, 2006). PCR products were separated
on 2% agarose gels and visualized by the Red Personal Gel Imaging System
(ProteinSimple). PCR products were also sequenced and found to match theports 4, 1108–1115, September 26, 2013 ª2013 The Authors 1113
expected LINE-1 sequence. The relative amount of synthesized cDNA from
bothmethods were then determined by real-time PCR using the primers Linker
(as part of primer 30RACE adaptor NV), 50-GCGAGCACAGAATTAATACGACT-
30; L1-LEAP-R, 50-GGGTTCGAAATCGATAAGCTTGGATCCAGAC-30, with a
standard two step method (95C for 15 s and 60C for 1 min) with a cycle
number of 40. See also Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at http://dx.doi.org/10.
1016/j.celrep.2013.08.019.
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